Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products

Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products

Publication: J Control Release
Software: GastroPlus®

Complex injectable drug products (CIDPs) have often been developed to modulate the pharmacokinetics along with efficacy for therapeutic agents used for remediation of chronic disorders.

Modeling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies

Modeling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies

Publication: AAPS J
Software: GastroPlus®

Model informed drug development (MiDD) is useful to predict in vivo exposure of drugs during various stages of the drug development process. This approach employs a variety of quantitative tools to assess the risks during the drug development process.

Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Publication: Cancer Nanotechnology
Software: ADMET Predictor®

The in vivo anticancer potential of vincristine (VC) loaded, thiolated chitosan-based nanoformulation (NFs) with an outer hyaluronic acid (VC-loaded in TCs-HA) coating was studied in prostate cancer (PC) xenograft in the immunosuppressed rat model induced by PC3 cell lines.

The application of AI-driven Drug Discovery technology for molecular optimization of nuclear receptor ligands

The application of AI-driven Drug Discovery technology for molecular optimization of nuclear receptor ligands

Authors: Bachorz RA
Conference: Ninth Joint Sheffield Conference on Chemoinformatics
Software: ADMET Predictor®
Division: PBPK

Nuclear receptors (NRs) are a superfamily of transcription factors whose activity is regulated upon the binding of a specific ligand.

Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies

Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies

Publication: Drugs in R&D
Software: GastroPlus®

Risk assessment related to bioequivalence study outcome is critical for effective planning from the early stage of drug product development.

Modeling time‐delayed concentration‐QT effects with ACT ‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist

Modeling time‐delayed concentration‐QT effects with ACT ‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist

Publication: Pharmacology Research & Perspectives

The novel oral complement factor 5a receptor 1 antagonist ACT- 1014- 6470 was well tolerated in single- and multiple- ascending dose studies, including 24 h Holter electro-cardiogram (ECG) recordings evaluating its cardiodynamics based on data from singledoses of 30– 200 mg and twice- daily (b.i.d.) dosing of 30– 120 mg for 4.5 days.

Gastroplus and HSPiP Oriented Predictive Parameters as the Basis of Valproic Acid Loaded Mucoadhesive Cationic Nanoemulsion Gel for Improved Nose-To-Brain Delivery to Control Convulsion in Human

Gastroplus and HSPiP Oriented Predictive Parameters as the Basis of Valproic Acid Loaded Mucoadhesive Cationic Nanoemulsion Gel for Improved Nose-To-Brain Delivery to Control Convulsion in Human

Publication: Preprints.org
Software: GastroPlus®

Oral and parenteral delivery of first-line anticonvulsant Valproic cid (VA) are associated with serious adverse effects, high hepatic metabolism, high clearance, and low bioavailability in brain.

Physiologically-Based Pharmacokinetic Modelling of Rivoceranib Parent and Metabolite to Project DDI Risk and Support Regulatory Decision-Making

Physiologically-Based Pharmacokinetic Modelling of Rivoceranib Parent and Metabolite to Project DDI Risk and Support Regulatory Decision-Making

Conference: DDI
Software: GastroPlus®
Division: PBPK

The PBPK model for rivoceranib, an anticancer drug acting as a tyrosine kinase inhibitor (TKI) that selectively targets vascular...

Using AI-driven Drug Design to Shorten Your Drug Development Process

Using AI-driven Drug Design to Shorten Your Drug Development Process

Software: ADMET Predictor®
Division: PBPK

In this webinar, Dr. Jeremy Jones, Principal Scientist, will discuss how artificial intelligence (AI) can be used in the drug discovery and development process to identify viable candidate molecules and shorten time to market.

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs

Authors: Deb S, Hopefl R
Publication: Daru Jour Pharma Sci
Software: GastroPlus®

Chemotherapy-induced nausea and vomiting are commonly experienced side effects in breast cancer (BCa) patients.